Mitogen-Activated Protein Kinase (MAPK) signalling pathways represent a fundamental means by which cells translate extracellular stimuli into a wide array of intracellular responses, including ...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
PAS-004 is being tested in a phase 1 trial for MAPK pathway-driven advanced solid tumors, with dosing initiated at 30 mg. The trial is multicenter, open-label, and dose-escalation, assessing safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results